Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.
作者： Ivana Gojo , Mariola Sadowska , Alison Walker , Eric J. Feldman , Swaminathan Padmanabhan Iyer
DOI: 10.1007/S00280-013-2249-Z
关键词:
摘要: Purpose Dinaciclib inhibits cyclin-dependent kinases 1, 2, 5, and 9 with a better therapeutic index than flavopiridol in preclinical studies. This study assessed the activity of dinaciclib acute leukemia both clinic vitro.
springer.com
core.ac.uk
mysciencework.com
elsevier.com参考文章(38)
J Pines, The cell cycle kinases. Seminars in Cancer Biology. ,vol. 5, pp. 305- 313 ,(1994)
Shinichi Kitada, Juan M. Zapata, Michael Andreeff, John C. Reed, Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood. ,vol. 96, pp. 393- 397 ,(2000) , 10.1182/BLOOD.V96.2.393.014K47_393_397
Lloyd T Lam, Oxana K Pickeral, Amy C Peng, Andreas Rosenwald, Elaine M Hurt, Jena M Giltnane, Lauren M Averett, Hong Zhao, R Eric Davis, Mohan Sathyamoorthy, Larry M Wahl, Eric D Harris, Judy A Mikovits, Anne P Monks, Melinda G Hollingshead, Edward A Sausville, Louis M Staudt, Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biology. ,vol. 2, pp. 1- 11 ,(2001) , 10.1186/GB-2001-2-10-RESEARCH0041
Robert G. Fenton, Bin Zhang, Ivana Gojo, The Cyclin-dependent Kinase Inhibitor Flavopiridol Induces Apoptosis in Multiple Myeloma Cells through Transcriptional Repression and Down-Regulation of Mcl-1 Clinical Cancer Research. ,vol. 8, pp. 3527- 3538 ,(2002)
K A Blum, A S Ruppert, J A Woyach, J A Jones, L Andritsos, J M Flynn, B Rovin, M Villalona-Calero, J Ji, M Phelps, A J Johnson, M R Grever, J C Byrd, Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol Leukemia. ,vol. 25, pp. 1444- 1451 ,(2011) , 10.1038/LEU.2011.109
J A Woyach, G Lozanski, A S Ruppert, A Lozanski, K A Blum, J A Jones, J M Flynn, A J Johnson, M R Grever, N A Heerema, J C Byrd, Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features. Leukemia. ,vol. 26, pp. 1442- 1444 ,(2012) , 10.1038/LEU.2011.375
Da Zhang, Monica Mita, Geoffrey I Shapiro, Jennifer Poon, Karen Small, Anjela Tzontcheva, Bhavna Kantesaria, Yali Zhu, Rajat Bannerji, Paul Statkevich, None, Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. ,vol. 70, pp. 891- 898 ,(2012) , 10.1007/S00280-012-1967-Y
Judith E. Karp, B. Douglas Smith, Linda S. Resar, Jacqueline M. Greer, Amanda Blackford, Ming Zhao, Dwella Moton-Nelson, Katrina Alino, Mark J. Levis, Steven D. Gore, Biju Joseph, Hetty Carraway, Michael A. McDevitt, Lorena Bagain, Karen Mackey, Janet Briel, L. Austin Doyle, John J. Wright, Michelle A. Rudek, Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias Blood. ,vol. 117, pp. 3302- 3310 ,(2011) , 10.1182/BLOOD-2010-09-310862
Geoffrey I. Shapiro, Cyclin-dependent kinase pathways as targets for cancer treatment. Journal of Clinical Oncology. ,vol. 24, pp. 1770- 1783 ,(2006) , 10.1200/JCO.2005.03.7689
Judit Garriga, Xavier Graña, Cellular control of gene expression by T-type cyclin/CDK9 complexes. Gene. ,vol. 337, pp. 15- 23 ,(2004) , 10.1016/J.GENE.2004.05.007